ORIENT-16

NCT03745170 📎

Regimen

Experimental
sintilimab + XELOX
Control
placebo + XELOX

Population

Chinese patients with HER2-negative advanced gastric/GEJ adenocarcinoma as first-line therapy

Key finding

All-comers mOS 15.2 vs 12.3 mo (HR 0.77, 95% CI 0.63-0.94, p=0.009); CPS>=5 mOS 18.4 vs 12.9 mo (HR 0.66, 95% CI 0.50-0.86, p=0.002)

Source: PMID 38051328

Timeline

    Guideline citations

    • CSCO GASTRIC 2025 (p.80)⚠️ OCR source